These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32047896)

  • 1. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.
    Schultz KR; Kariminia A; Ng B; Abdossamadi S; Lauener M; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savasan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Azadpour S; Ostroumov E; Subrt P; Halevy A; Mostafavi S; Cuvelier GDE
    Blood; 2020 Apr; 135(15):1287-1298. PubMed ID: 32047896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
    Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
    Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease.
    Subburaj D; Ng B; Kariminia A; Abdossamadi S; Lauener M; Nemecek ER; Rozmus J; Kharbanda S; Kitko CL; Lewis VA; Schechter-Finklestein T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Coulter D; Chewning JH; Joyce M; Pawlowska AB; Megason GC; Lawitschka A; Ostroumov E; Klein Geltink R; Cuvelier GDE; Schultz KR
    Blood; 2022 Jan; 139(2):287-299. PubMed ID: 34534280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
    Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
    Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
    Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy.
    Takahashi T; Arora M; Okoev G; DeFor TE; Weisdorf DJ; MacMillan ML
    Transplant Cell Ther; 2021 Aug; 27(8):667.e1-667.e5. PubMed ID: 34077812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation".
    Cuvelier GDE; Li A; Drissler S; Kariminia A; Abdossamadi S; Rozmus J; Chanoine JP; Ng B; Mostafavi S; Brinkman RR; Schultz KR
    Front Immunol; 2020; 11():571884. PubMed ID: 33193355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.
    Cuvelier GDE; Ng B; Abdossamadi S; Nemecek ER; Melton A; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Ostroumov E; Schultz KR
    Blood Adv; 2023 Jul; 7(14):3612-3623. PubMed ID: 36219586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shaping of CD56
    Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2019; 10():547. PubMed ID: 30949182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune cell subset counts associated with graft-versus-host disease.
    Podgorny PJ; Liu Y; Dharmani-Khan P; Pratt LM; Jamani K; Luider J; Auer-Grzesiak I; Mansoor A; Williamson TS; Ugarte-Torres A; Hoegh-Petersen M; Stewart DA; Daly A; Khan FM; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):450-62. PubMed ID: 24406506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
    Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of pDCs, mDCs, γδT cells and regulatory T cells in association with graft versus host disease after hematopoietic stem cell transplantation.
    Watanabe N; Narita M; Furukawa T; Nakamura T; Yamahira A; Masuko M; Toba K; Fuse I; Aizawa Y; Takahashi M
    Int J Lab Hematol; 2011 Aug; 33(4):378-90. PubMed ID: 21692996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
    Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
    Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.
    Wang L; Ni M; Hückelhoven-Krauss A; Sellner L; Hoffmann JM; Neuber B; Luft T; Hegenbart U; Schönland S; Kleist C; Sill M; Chen BA; Wuchter P; Eckstein V; Krüger W; Hilgendorf I; Yerushalmi R; Nagler A; Müller-Tidow C; Ho AD; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2018; 9():2207. PubMed ID: 30349527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
    Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
    Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
    Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
    Front Immunol; 2020; 11():1534. PubMed ID: 32849519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.